Intimate associations exist between atherosclerosis and inflammation. The atherosclerotic process itself has features of chronic inflammation. Furthermore, the process of atherosclerosis is markedly accelerated by chronic inflammatory disease states such as rheumatoid arthritis. Perhaps most notable among the plethora of metabolic changes that affect lipid and lipoproteins during inflammation are the structural and metabolic alterations of HDL.

Serum amyloid A protein (SAA) becomes a major apolipoprotein of HDL during the acute phase and can replace apoA-I as the major HDL apolipoprotein. Concomitant with SAA induction is a decline in plasma HDL cholesterol and apoA-I levels. Notable lipid changes occur, and HDL becomes generally enriched in triglycerides.

The scavenger receptor class B type I (SR-BI) plays an important role in the metabolism of high-density lipoprotein (HDL). It binds HDL with high affinity and by selective lipid uptake mediates the movement of cholesterol ester from the hydrophobic HDL core to the cell. SR-BI-mediated selective lipid uptake generates incrementally smaller and denser HDL particles (HDL remnants). With respect to normal human HDL, these remnants are not rapidly cleared from the circulation but rather remodel to form large HDL particles by association with existing lipoprotein particles, preferably HDL. A portion of the HDL remnant apolipoproteins is directed toward catabolism.

We used 2 model systems to study the interactions between SR-BI and SAA-containing acute phase HDL (AP HDL). The first is an established model where the metabolic fate of radiolabeled AP HDL in mice over expressing SR-BI is evaluated. The second involves monitoring the effect of dual SR-BI and SAA adenoviral expression on endogenous HDL metabolism. The latter approach mimics the acute phase as SAA is predominantly produced in the liver. Data indicate that SR-BI action segregates AP HDL apolipoprotein metabolism. Discrete AP HDL remnant particles with distinct apolipoprotein compositions are generated. The presence of SAA on AP HDL remnants tends to propel apoA-I to small lipid poor forms potentially impacting efflux while at the same time accelerating apoA-I catabolism.

**Methods**

**Animals**

C57BL/6 and apoA-I−/− (C57BL/6 background) mice were obtained from Jackson Laboratories. An acute phase response was elicited by intraperitoneal injection of 25 or 100 μg lipopolysaccharide (LPS; *Escherichia coli* 0111:B4, Sigma Chemical Company). After 24 hours the mice were humanely killed and AP HDL isolated from plasma by sequential ultracentrifugation. The Veterans Administration Medical Center Institutional Animal Care and Use Committee approved all procedures.

**Lipoprotein Isolation and Radiolabeling**

HDL (d=1.063 to 1.21 g/mL) was isolated from fresh mouse plasma by density gradient ultracentrifugation. HDL was dialyzed against...
150 mmol/L NaCl, 0.01% EDTA, sterile filtered, and stored under argon at 4°C. Protein concentrations were determined by the method of Lowry et al. The apolipoprotein content of HDL fractions was determined by densitometric scanning of Coomassie stained SDS-gels. HDL was radiolabeled by the iodine monochloride method.

**Generation of HDL Remnants in apoA-I−/− Mice**

The production of SR-BI–generated HDL remnants in apoA-I−/− mice was described. −/− ApoA-I−/− mice weighing at least 25 g were tail vein injected with 1.5×1011 particles AdSR-BI, a replication-defective adenoviral vector expressing mouse SR-BI, or Adnull, a control vector containing no transgene. Three days after adenovirus infusion, mice were injected via the jugular vein with a bolus of 700 μg AP HDL traced with 50 μg 125I-AP HDL in 100 μL saline (specific activity of HDL mix 20 to 43 cpm/ng). Plasma aliquots (~20 μL) were obtained for analysis at selected times up to 5 hours after bolus administration. By analyzing aliquots from each of the time points by native gel electrophoresis, we assessed the kinetics of remnant generation in 2 separate experiments. In this model apoA-I−/− mice contain virtually no endogenous lipoproteins. The concentration of HDL remnants in plasma was determined from the counts recovered in the mouse plasma and the known specific activity of the injected 125I-HDL.

**In Vitro Remodeling Reactions**

Plasma containing HDL remnants, collected from mice at selected times after bolus injection, was mixed 1:10 (v:v) with mouse HDL (1.7 mg/mL). After incubations at 37°C, the remodeling reactions were transferred to ice, mixed with an equal volume of saturated sucrose, and immediately applied to a nondenaturing gradient gel and visualized by autoradiography. The apolipoprotein composition of remnant particles or remodeled particles was determined by excising bands from nondenaturing gels, and analyzing by SDS-PAGE and autoradiography.

**SR-BI and SAA Dual Adenoviral Vector Model**

Replication-defective adenoviral vectors expressing SR-BI or SAA and a control vector containing no transgene (Adnull) were used. AdSR-BI expressed mouse SR-BI and was used at 0.5×1011 particles, titrated to increase hepatic SR-BI expression approximately 3-fold. This resulted in a 50% decline in HDL levels. The SAA adenoviral vector (AdSAA) expressed the CEJ isotype of mouse SAA and was used at 1×1011 particles. This increased SAA levels approximately 8-fold without impacting HDL levels. Four groups of C57BL/6 mice (n=4) were injected with identical total amounts of adenoviral vector particles (1.5×1011) in 1 of 4 combinations, consisting of AdSR-BI plus Adnull, AdSAA plus Adnull, AdSR-BI plus AdSAA, or Adnull only. Blood was collected at 24 and 48 hours by retro-orbital bleeding and the experiment terminated at 72 hours. Western blot analyses were used to verify consistent SR-BI and SAA expression at 72 hours. Plasma HDL levels were measured (Wako Diagnostics). The apoA-I and SAA distribution with respect to HDL was analyzed at 72 hours by nondenaturing gradient gel electrophoresis followed by immunoblot analysis for either mouse apoA-I (Biodesign) or mouse SAA (Rabbit anti-mouse SAA, F.C.D. laboratory).

**Statistical Analysis**

Data are presented as mean±SEM. Statistical analyses to compare differences between plasma HDL levels were carried out using 1-way ANOVA with the Holm-Sidak multiple comparisons test (SigmaStat 3.5, GmbH). Significance was set at P<0.05.

**Results**

**SR-BI and AP HDL Apolipoprotein Clearance**

To study AP HDL apolipoprotein metabolism after processing by SR-BI, we initially used an established model in which SR-BI was overexpressed in apoA-I−/− mice by means of an adenoviral vector. In our model a bolus of mouse AP HDL traced with 125I was injected into mice 3 days after viral vector, and plasma samples were collected at selected intervals. ApoA-II is drastically reduced when SAA is a major apolipoprotein of HDL. To compare the clearance of SAA and apoA-II during SR-BI processing, we chose to use AP HDL from mice injected with 25 μg LPS that contained moderate amounts of SAA and apoA-II (SAA≈33%; apoA-II≈14% of total protein, respectively; Figure 1A). AP HDL from mice injected with 100 μg LPS in which SAA constitutes ≈43% of total protein and apoA-II only ≈6% of total protein was used for subsequent experiments to focus on SAA (Figure 1A). The apolipoprotein composition of HDL with moderate SAA content (25 μg injected LPS), when processed by SR-BI, was determined by direct SDS PAGE and autoradiography of plasma samples collected at the indicated times after bolus AP HDL injection. This analysis showed a very rapid loss from the circulation of SAA and apoA-II compared to apoA-I when SR-BI was overexpressed (Figure 1B and 1C).

**AP HDL Remodeling In Vivo**

The size of mouse AP HDL particles after SR-BI processing was determined by direct analysis of plasma samples by means of nondenaturing gel electrophoresis and autoradiography (Figure 2A). In this model system, exogenously administered mouse AP HDL (from mice injected with 100 μg

**Figure 1.** A, Apolipoprotein composition of mouse HDL. HDL from mice injected with 25 or 100 μg LPS was subjected to SDS-PAGE analysis on a 5% to 20% acrylamide gradient gel and stained with Coomassie blue. HDL loading, 5 μg/lane. Quantitation was by densitometric scanning. B, Preferential loss of apoA-II and SAA after SR-BI processing. ApoA-I−/− mice were injected with 1.5×1011 particles of adenoviral vector AdSR-BI. After 3 days when SR-BI expression was maximal, the mice were injected with a bolus of 750 μg 125I-AP HDL (25 μg LPS). Plasma samples containing remnants were collected from individual mice at the indicated times after bolus injection and 5 μL aliquots were analyzed by SDS-PAGE (5% to 20% acrylamide gradient). An aliquot of the injected 125I-AP HDL is shown for comparison. Samples were visualized by autoradiography. C, No preferential loss of apoA-II and SAA without SR-BI processing. ApoA-I−/− mice were injected with a bolus of 750 μg 125I-AP HDL and plasma samples collected and analyzed as in 1B.
LPS) became progressively smaller with the formation of HDL remnants occurring in incremental steps (Figure 2A). No lipid free apolipoproteins were detected. Short term SR-BI processing \( (\sim 1 \text{ hour}) \) reduced the size of exogenous AP HDL from 10.2 nm to a remnant particle (R1) with a diameter of approximately 9.8 nm (Figure 2A). Intermediate processing (3 hours) resulted in the formation of 2 distinct remnant particles R2 and R3 with diameters of approximately 9.4 and 7.6 nm, respectively (Figure 2A). Prolonged processing (5 hours) led to the formation of a predominant population of R3 particles (Figure 2A). These dense and small R3 particles could not be refloated by density gradient centrifugation, but were larger than “free” apoA-I.6 They appear to be the final stage of SR-BI processing, but can be detected early in this process (0.5 hours). The apolipoprotein composition of the AP HDL remnants was assessed by excising corresponding bands from the gel depicted in Figure 2A and analyzing them by SDS-PAGE (Figure 2B). The injected \( ^{125} \text{I} \) AP HDL contained predominantly apoA-I and SAA with apoA-II constituting less than 10% of the apolipoproteins (Figures 1A and 2B). One hour of SR-BI processing generated a R1 remnant that was similar in apolipoprotein content to the starting HDL and a R3 remnant that contained predominantly apoA-I (Figure 2B). The R2 remnants at 3 and 5 hours contained mainly apoA-I and SAA (Figure 2B). R3 remnants at these times were enriched for apoA-I with only small amounts of SAA detected. ApoA-II was not detected at these later time points.

AP HDL Remnant Association With HDL

We have reported that similarly produced remnants from normal human HDL associate with preformed HDL.7 We determined whether the AP HDL remnants varied in their ability to associate with HDL. For these studies, plasma samples collected at selected intervals after bolus injection of \( ^{125} \text{I} \) AP HDL were incubated with unlabeled C57BL/6 mouse HDL, analyzed by nondenaturing gradient gel electrophoresis and autoradiography to visualize apolipoprotein originally present in SR-BI-processed remnants (Figure 3A). AP HDL excised from the same non denaturing gel is shown for comparison.
By 3 hours, SR-BI processing generated a subpopulation of AP HDL remnants that appeared to be resistant to HDL association (band B). Longer SR-BI processing (5 hours) resulted in the generation of increasing amounts of the resistant remnant (band B; Figure 3A). Bands corresponding to T and B were excised from the nondenaturing gel (Figure 3A) and subjected to SDS PAGE (Figure 3B). The $^{125}\text{I}$-AP HDL remnant that was resistant to HDL association (band B) contained only apoA-I. The larger remodeled remnant (T) contained apoA-I, SAA, and apoA-II. As AP HDL is processed by SR-BI, progressively more remnant particles are generated that are resistant to associating with HDL. These remodeling-resistant remnants contain mainly apoA-I, whereas remnants capable of remodeling by association of HDL contain apoA-I, SAA and apoA-II.

**SR-BI and SAA Coexpression**

Data presented in Figure 4 indicate that expression of Adnull alone, or in combination with AdSAA, has no significant effect on HDL levels in C57BL/6 mice. A moderate level of SR-BI over expression (3-fold over control) by AdSR-BI, decreased HDL levels by approximately 50% to 35 mg/dL at 72 hours. Interestingly, overexpression of SAA together with SR-BI, progressively more remnant particles are generated that are resistant to associating with HDL. These remodeling-resistant remnants contain mainly apoA-I, whereas remnants capable of remodeling by association of HDL contain apoA-I, SAA and apoA-II.

![Figure 4](image1.png)

**Figure 4.** HDL levels of mice after injection of adenoviral vectors expressing SAA, SR-BI, or SR-BI plus SAA. Four groups of mice (n=4) were injected with $1.5 \times 10^{11}$ particles of adenovirus expressing SR-BI, SAA, or SR-BI plus SAA as set out in Methods. HDL cholesterol was measured at the indicated times after viral injection. a, 0 hours vs 48 hours vs 72 hours, P < 0.05. b, 48 hours vs 72 hours, P < 0.05. c, AdSR-BI plus Adnull vs AdSR-BI plus AdSAA 72 hours, P < 0.05.

![Figure 5](image2.png)

**Figure 5.** Combined action of SR-BI and SAA generate small HDL particles containing apoA-I but not SAA. Plasma (3 μL) collected from 4 individual mice 72 hours after administration of Adnull, AdSAA, AdSRBI, or combinations of viruses as set out in Methods were subjected to nondenaturing gel electrophoresis on a 4% to 20% acrylamide gel, transferred to PVDF, and blotted for apoA-I (A) or SAA (B).

**Discussion**

HDL remodeling in plasma plays an important role in regulating HDL levels and metabolism, including the generation of lipid-free and lipid-poor apolipoproteins that can function as acceptors in cellular cholesterol efflux. Remodeling studies of polydisperse human HDL are difficult. The impact of inflammation on HDL compounds this problem. Mouse HDL is relatively homogeneous and lack particles containing only apoA-I, allowing for simplified interpretation. Data presented in this article support the following: (1) SR-BI processing of mouse AP HDL in vivo generated progressively smaller, discreet remnant HDL particles with distinct apolipoprotein compositions. (2) SR-BI processing of mouse AP HDL segregated apolipoproteins in that the smallest particles contained only apoA-I, whereas larger remnant particles contained apoA-I, apoA-II, as well as SAA. (3) The small particles that contained only apoA-I failed to associate with mouse HDL, whereas the larger remnants readily associated with preformed HDL. (4) SAA association with SR-BI processed HDL particles moved apoA-I to a small lipid poor form, which holds implications for cholesterol efflux, and also accelerates apoA-I catabolism.

Our data indicate that SR-BI overexpression has a major influence on the rate of apolipoprotein catabolism with the different apolipoproteins of AP HDL clearing at different rates. The implication is that under normal conditions the metabolic segregation of apolipoproteins is mediated by SR-BI, but on a more limited scale. Thus the known difference in clearance rates of HDL apolipoproteins could be the result of SR-BI action. The degree to which inflammation could alter the various structural and functional class B scavenger receptor modalities merits consideration. Studies
of the binding kinetics of SR-BI to different ligands suggest that SR-BI exists in different functional forms with dimerization reported.14,15 There are 2 further distinct isoforms (SR-BI and SR-BII) that have different functions and distribution.16 Certain HDL particles could be subjected to more intense SR-BI action, resulting in the apolipoprotein manifestations that we present. Although the experimental conditions are in a nonsteady state and detailed kinetic interpretations are not warranted, it is clear that SAA clears more rapidly than apoA-II. Given that SAA was reported to be a ligand for SR-BI and that SAA was internalized by cells in a SR-BI–dependent manner,17 the possibility exists that SAA is directly taken up by hepatocytes from the space of Disse.

SR-BI processing results in progressively smaller AP HDL with 3 discrete small remnants emerging (R1, R2, and R3) that are generated in incremental steps. As SR-BI associates preferentially with large HDL particles, one potential reason for the accumulation of smaller particles of discrete size is the possibility that as HDL become smaller, they lose their ability to interact with SR-BI.18 Accumulated remnants after AP HDL injection may represent subpopulations of HDL that differ markedly in their affinity for SR-BI. An alternative explanation for the incremental changes in AP HDL particle size may be physical constraints in HDL particle structure allowing only for discreet entities to stably exist.

There is a remarkable segregation of apolipoproteins with respect to the remnants formed. It is notable that the small predominantly apoA-I remnant (R3) is rapidly generated, albeit only in small amounts. Central to apoA-I dissociation from HDL during remodeling is a reduction in core lipids, as for instance mediated by cholesteryl ester transfer protein (CETP).19,20 Hydrolysis of HDL surface phospholipids by acute phase phospholipases, notably Group IIA secretory phospholipase A2 (IIA sPLA2), reduce HDL size, and alter apoA-I epitopal expression but does not per se result in apoA-I liberation from the particle.20 However, concomitant HDL core reduction by CETP and surface hydrolysis by IIA sPLA2 markedly amplified the movement of apoA-I from HDL to lipid-poor forms.20 SR-BI selective lipid uptake is similar to the latter in that transfer of cholesteryl ester from the core of the HDL particle is associated with movement of surface phospholipids to the cell. The shedding of a predominantly apoA-I remnant is thus not surprising as apoA-I is the least lipophilic of the HDL apolipoproteins with the highly lipophilic SAA promoting this process.

We have previously reported that normal human HDL remnants, when mixed with mouse plasma either in vivo or in vitro, increase in size to HDL-like particles.6,7 It was of interest to determine whether the AP HDL remnants containing different amounts of apoA-I, SAA, and apoA-II vary in their ability to associate with HDL. Data indicate that as for normal human HDL, the apoA-I-only remnant (R3) is resistant to HDL association.8 SAA- and apoA-II–containing remnants sustain a structural organization that allows reassociation with existing HDL. It is remarkable that the small apoA-I only particle (R3) does not reassociate with normal HDL. This clearly distinguishes it from pre-β HDL or free apoA-I.21 It suggests a rather unique conformation of the apoA-I on this remnant, possibly similar to the small apoA-I-only HDL particles isolated by anti-human apoA-I immunoaffinity chromatography.21

The second model using dual adenoviral vector expression of SR-BI and SAA expands our understanding of acute phase HDL remodeling. The SAA expression effected is physiologically relevant and equates to a “moderate” inflammatory response. SAA is mostly produced in the liver where it could impact the formation of HDL. Data indicate that in the absence of enhanced selective lipid uptake by SR-BI, SAA does not influence apoA-I distribution or HDL levels. However, when selective lipid uptake is increased it has a potent affect to propel apoA-I to a smaller form and decrease HDL levels. Apart from putative alterations in SR-BI function, other factors have been shown to enhance HDL selective lipid uptake during inflammation. Most notable is the acute phase secreted phospholipases such as group IIA sPLA2 and endothelial lipase (EL).22,23 Modification of HDL by these enzymes result in markedly enhanced selective uptake with subsequent increase in HDL catabolism and decreased plasma HDL levels. When HDL core and surface lipid content is thus perturbed, SAA clearly holds the potential to dramatically alter the equilibrium between HDL-bound and lipid-poor apoA-I. This holds implications for interpreting the data presented using our first model. The likelihood is that the continual presence of SAA on remnants serves to propel more apoA-I to lipid poor forms. This suggest that SAA could promote cholesterol efflux by not only serving as an extracellular cholesterol acceptor, but also by liberating apoA-I.24

Cholesterol acceptors need to be available particularly in extracellular spaces where efflux occurs.19 Proteins secreted by cholesterol-loaded macrophages, including acute phase secreted phospholipases, phospholipid transfer protein, cholesterol ester transfer protein, hepatic lipase, and lipoprotein lipase, could play a key role in HDL remodeling within the vascular subendothelium, including the space of Disse, which leads in part to the generation of lipid poor apoA-I.19,25 Numerous cells in these spaces produce SAA under inflammatory conditions where it could act to further propel apoA-I to lipid poor forms from remodeled remnants.

The generation of increased lipid poor apoA-I by SAA during HDL remodeling clearly comes at the potential price of enhanced catabolism and decreased HDL levels. It is likely too limited to view SAA as either pro- or antiatherogenic. It is the context in which SAA is expressed, particularly with respect to amount, duration, and presence of HDL modifying factors that could have varying effects. Teleologically, the dramatic changes in HDL composition and metabolism during inflammation likely serves a shorter term purpose to allow the organism to survive a noxious assault. Longer-term inflammation could be deleterious in that HDL levels may become so reduced that there is a lack of “substrate” to derive lipid acceptors from.

**Sources of Funding**

This work was supported by NIH award PO1 HL086670 and VA Merit Review Funds (to F.C.d.B.).
Disclosures

None.

References

SR-BI Selective Lipid Uptake. Subsequent Metabolism of Acute Phase HDL
Maria C. de Beer, Nancy R. Webb, Nathan L. Whitaker, Joanne M. Wroblewski, Anisa
Jahangiri, Deneys R. van der Westhuyszen and Frederick C. de Beer

Arterioscler Thromb Vasc Biol. published online March 19, 2009;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/early/2009/03/19/ATVBAHA.109.186502.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/